Anil Rustgi named cancer center director at Columbia, New York-Presbyterian

New FDA mandate to tell patients whether their breasts are “dense” or “not dense” baffles doctors
Problem: “Breast density is in the eye of the mammographer”

Collage art of mammograms of dense breastsIllustrator: Cyrus FineganWhile breast cancer experts are anything but clear on what the words “dense breasts” signify in the clinic, or for that matter, in the English language, FDA appears to be less perplexed.

September 27, 2024

Vol.50 No.36

By Claire Marie Porter

Regulatory News

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

September 27, 2024

Vol.50 No.36

By Jacquelyn Cobb

PubMed’s failure to display all papers by authors who publish under multiple names “mistreats women,” lawsuit contends

A law group associated with conservative causes and funded by leading conservative donors has sued NIH, HHS, and the National Library of Medicine, demanding that the institutions address PubMed’s inability to display all papers authored by researchers who have published under multiple names.

September 27, 2024

Vol.50 No.36

By Jacquelyn Cobb

Cancer History Project Guest Editorial

How First Lady Betty Ford and surgeon Bernie Fisher revolutionized America’s attitude toward breast cancer

It is rare that an ABC Movie of the Week endures. Buzz Kulik’s 1971 “Brian’s Song” is a notable exception.

Jose and Irma Russo— husband and wife trailblazers in breast cancer research

Jose and Irma Russo dedicated their careers to investigating breast cancer, its causes, and potential prevention measures.

September 27, 2024

Vol.50 No.36

In Brief

Sanya Springfield named NCI acting deputy director for health equity and inclusion

Sanya A. Springfield will join the Office of the NCI Director as an acting deputy director, charged with broadening and strengthening cancer health equity and inclusion programs, effective in the coming weeks.

September 27, 2024

Vol.50 No.36

Anil Rustgi named cancer center director at Columbia, New York-Presbyterian

YOU MAY BE INTERESTED IN

New FDA mandate to tell patients whether their breasts are “dense” or “not dense” baffles doctors
Problem: “Breast density is in the eye of the mammographer”

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

PubMed’s failure to display all papers by authors who publish under multiple names “mistreats women,” lawsuit contends

How First Lady Betty Ford and surgeon Bernie Fisher revolutionized America’s attitude toward breast cancer

Jose and Irma Russo— husband and wife trailblazers in breast cancer research

Sanya Springfield named NCI acting deputy director for health equity and inclusion

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login

Anil Rustgi named cancer center director at Columbia, New York-Presbyterian

YOU MAY BE INTERESTED IN

New FDA mandate to tell patients whether their breasts are “dense” or “not dense” baffles doctorsProblem: “Breast density is in the eye of the mammographer”

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitorsVote applies across drugs and indications

PubMed’s failure to display all papers by authors who publish under multiple names “mistreats women,” lawsuit contends

How First Lady Betty Ford and surgeon Bernie Fisher revolutionized America’s attitude toward breast cancer

Jose and Irma Russo— husband and wife trailblazers in breast cancer research

Sanya Springfield named NCI acting deputy director for health equity and inclusion

Can you spare 10 minutes to complete a survey?

Login

New FDA mandate to tell patients whether their breasts are “dense” or “not dense” baffles doctors
Problem: “Breast density is in the eye of the mammographer”

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications